marizomib (NPI-0052)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for marizomib (NPI-0052), covering 2017-11-22 to 2017-11-22. Get the full timeline:
Most recent: Clinical Trial Update: NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma [Phase 1]